Roche's Columvi Meets Main Goal in Lymphoma Phase 3 Trial
By Adria Calatayud
Roche Holding said its Columvi drug helped lymphoma patients who had received at least one prior treatment live longer in a phase 3 clinical trial, meeting the primary goal of the study.
The Swiss pharmaceutical giant said Monday that Columvi, in combination with chemotherapy, showed a statistically significant improvement in overall survival for people with diffuse large B-cell lymphoma--a form of blood cancer--who had received at least one prior line of therapy and weren't candidates for transplant of their own stem cells.
Roche said safety of the drug combination appeared consistent with the known safety profiles of the individual medicines.
Data from the trial will be submitted to health authorities, the company said. Roche intends to publish more details at an upcoming medical meeting, it said.
Columvi already received approval by the U.S. Food and Drug Administration and conditional authorization from the European Commission to treat people with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of therapy, Roche said.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
April 15, 2024 01:39 ET (05:39 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening in the Markets This Week
-
4 Top Dividend-Paying REIT Stock Picks
-
After Earnings, Is Netflix Stock a Buy, a Sell, or Fairly Valued?
-
P-CAPE: A Better Way for Investors to Estimate Future Returns
-
Which Stocks Have Driven the Stealth Large-Value Rally?
-
Forecasts for Q2 GDP Report Show a Healthy but Slowing Economy
-
5 Stocks to Buy as the Market Rally Broadens
-
4 Top US Travel Stock Picks
-
How Do Interest Rates Affect Stock Market Returns?
-
American Airlines Earnings: Ticket Distribution Misstep Affected Results
-
Going Into Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
3 Top Cybersecurity Stock Picks for Long-Term Investors
-
AbbVie Earnings: Firm Sees Strong Next-Generation Immunology Drugs Sales
-
Ford Earnings: Warranty Problems on Older Vehicles Slam Results
-
ServiceNow Earnings: Operating on a Higher Plane Within Enterprise Software